Login Register Cart 0
Generic placeholder image

Current Diabetes Reviews

Editor-in-Chief

ISSN (Print): 1573-3998
ISSN (Online): 1875-6417

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

Prevalence and Co-prevalence of Comorbidities among Patients with Type 2 Diabetes Mellitus in the MENA Region: A Systematic Review

Author(s): Samir Assaad Khalil*, Sami Azar, Khadija Hafidh, George Ayad and Mohamed Safwat

Volume 20, Issue 7, 2024

Published on: 26 October, 2023

Article ID: e310723219277 Pages: 6

DOI: 10.2174/1573399820666230731105704

Price: $65

Abstract

Aim: The management of type 2 diabetes mellitus is affected by the presence of comorbidities. This meta-analysis aimed to determine how likely it is for individuals with type 2 diabetes in the Middle East and North Africa (MENA) region to be living with additional chronic health conditions.

Methods: We searched for studies published from January 2010 to December 2020 in the PubMed, Ovid MEDLINE®, Cochrane CENTRAL, Scopus, and Web of Science databases. Studies of adults with type 2 diabetes in the MENA region were included. We performed a random-effects meta-analysis of single proportions to calculate each comorbidity's overall prevalence/coprevalence.

Results: Statistically significant co-prevalence was detected at p < 0.01 for angina (pooled proportion: 0.24, 95% CI: 0.06, 0.49), cerebrovascular accident (pooled proportion: 0.16, 95% CI: 0.08, 0.26), coronary artery disease (pooled proportion: 0.25, 95% CI: 0.16, 0.35), coronary heart disease (pooled proportion: 0.05, 95% CI: 0.01, 0.12), peripheral vascular disease (pooled proportion: 0.19, 95% CI: 0.13, 0.26), hypertension (pooled proportion: 0.56, 95% CI: 0.43, 0.69), renal impairment (pooled proportion: 0.19, 95% CI: 0.10, 0.29), in addition to hyperlipidemia and overweight/ obesity.

Conclusion: There is evidence of co-prevalence of several comorbidities in patients with type 2 diabetes, highlighting the importance of enhancing communication among healthcare professionals to develop the optimal management plan for each patient.

[1]
Correa MF, Li Y, Kum HC, Lawley MA. Assessing the effect of clinical inertia on diabetes outcomes: A modeling approach. J Gen Intern Med 2019; 34(3): 372-8.
[http://dx.doi.org/10.1007/s11606-018-4773-3] [PMID: 30565149]
[2]
Diabetes Federation International IDF Diabetes Atlas 2019. International Diabetes Federation 2019.
[3]
Kalan Farmanfarma KH, Ansari-Moghaddam A, Zareban I, Adineh HA. Prevalence of type 2 diabetes in Middle–East: Systematic review& meta-analysis. Prim Care Diabetes 2020; 14(4): 297-304.
[http://dx.doi.org/10.1016/j.pcd.2020.01.003] [PMID: 32044288]
[4]
Pantalone KM, Hobbs TM, Wells BJ, et al. Clinical characteristics, complications, comorbidities and treatment patterns among patients with type 2 diabetes mellitus in a large integrated health system. BMJ Open Diabetes Res Care 2015; 3(1): e000093.
[http://dx.doi.org/10.1136/bmjdrc-2015-000093] [PMID: 26217493]
[5]
Iglay K, Hannachi H, Howie PJ, Xu J, Li X, Engel SS. Prevalence and co-prevalence of comorbidities among patients with type 2 diabetes mellitus 2016; 32(7): 1243-52.
[http://dx.doi.org/10.1185/03007995.2016.1168291]
[6]
Hussain S, Chowdhury TA. The impact of comorbidities on the pharmacological management of type 2 diabetes mellitus. Drugs 2019; 79(3): 231-42.
[http://dx.doi.org/10.1007/s40265-019-1061-4] [PMID: 30742277]
[7]
Chung WK, Erion K, Florez JC, et al. Precision medicine in diabetes: A consensus report from the American diabetes association (ada) and the european association for the study of diabetes (EASD). Diabetes Care 2020; 43(7): 1617-35.
[http://dx.doi.org/10.2337/dci20-0022] [PMID: 32561617]
[8]
Costello RA, Nicolas S, Shivkumar A. In Treasure Island, FL: Sulfonylureas 2023.
[9]
Johnson EL, Feldman H, Butts A, Chamberlain J, Collins B, Doyle-Delgado K. Standards of medical care in diabetes-2020 abridged for primary care providers. Clin Diabetes 2020; 38(1): 10-38.
[http://dx.doi.org/10.2337/cd20-as01] [PMID: 31975748]
[10]
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339(Jul 21): b2535.
[http://dx.doi.org/10.1136/bmj.b2535] [PMID: 19622551]
[11]
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Wiley. In: Wiley Cochrane Series 2011.
[12]
Stokes T, Tumilty E, Doolan-Noble F, Gauld R. Multimorbidity, clinical decision making and health care delivery in New Zealand Primary care: A qualitative study. BMC Fam Pract 2017; 18(1): 51.
[http://dx.doi.org/10.1186/s12875-017-0622-4] [PMID: 28381260]
[13]
Valderas JM, Gangannagaripalli J, Nolte E, et al. Quality of care assessment for people with multimorbidity. J Intern Med 2019; 285(3): joim.12881.
[http://dx.doi.org/10.1111/joim.12881] [PMID: 30719790]
[14]
Zhang L, Shooshtari S, John PS, Menec VH. Multimorbidity and depressive symptoms in older adults and the role of social support: evidence using canadian longitudinal study on aging (CLSA) data. PLoS One 2022; 17: 1-21.
[http://dx.doi.org/10.1371/journal.pone.0276279]
[15]
Aggarwal A, Patel P, Lewison G, et al. The profile of non-communicable disease (ncd) research in the middle east and north africa (mena) region: Analyzing the ncd burden, research outputs and international research collaboration. PLoS One 2020; 15(4): e0232077.
[http://dx.doi.org/10.1371/journal.pone.0232077] [PMID: 32339197]
[16]
Ogurtsova K, da Rocha Fernandes JD, Huang Y, et al. IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract 2017; 128: 40-50.
[http://dx.doi.org/10.1016/j.diabres.2017.03.024] [PMID: 28437734]
[17]
Hermans MP, Dath N. Prevalence and co-prevalence of comorbidities in Belgian patients with type 2 diabetes mellitus: a transversal, descriptive study 2017; 73(1): 68-74.
[18]
Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007–2017. Cardiovasc Diabetol 2018; 17(1): 83.
[http://dx.doi.org/10.1186/s12933-018-0728-6] [PMID: 29884191]
[19]
Aschner P, Gagliardino JJ, Ilkova H, et al. Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 Years of real-world evidence of the international diabetes management practices study (IDMPS). Diabetologia 2020; 63(4): 711-21.
[http://dx.doi.org/10.1007/s00125-019-05078-3] [PMID: 31901950]
[20]
Wagnew F, Eshetie S, Kibret GD, et al. Diabetic nephropathy and hypertension in diabetes patients of sub-Saharan countries: A systematic review and meta-analysis. BMC Res Notes 2018; 11(1): 565.
[http://dx.doi.org/10.1186/s13104-018-3670-5] [PMID: 30081966]
[21]
Kaze AD, Santhanam P, Musani SK, Ahima R, Echouffo-Tcheugui JB. Metabolic dyslipidemia and cardiovascular outcomes in type 2 diabetes mellitus: Findings from the look ahead study. J Am Heart Assoc 2021; 10(7): e016947.
[http://dx.doi.org/10.1161/JAHA.120.016947] [PMID: 33728932]
[22]
Alharbi NS, Almutari R, Jones S, Al-Daghri N, Khunti K, de Lusignan S. Trends in the prevalence of type 2 diabetes mellitus and obesity in the Arabian Gulf States: Systematic review and meta-analysis. Diabetes Res Clin Pract 2014; 106(2): e30-3.
[http://dx.doi.org/10.1016/j.diabres.2014.08.019] [PMID: 25241351]
[23]
Wallace E, Salisbury C, Guthrie B, Lewis C, Fahey T, Smith SM. Managing patients with multimorbidity in primary care. BMJ 2015; 350(Jan 20): h176.
[http://dx.doi.org/10.1136/bmj.h176] [PMID: 25646760]
[24]
Skou ST, Mair FS, Fortin M, Guthrie B, Nunes BP, Miranda JJ. Multimorbidity. Nat Rev Dis Prim 2022; 8(1)
[25]
Ong KY, Lee PSS, Lee ES. Patient-centred and not disease-focused: A review of guidelines and multimorbidity. Singapore Med J 2020; 61(12): 584-90.
[http://dx.doi.org/10.11622/smedj.2019109] [PMID: 31489434]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy